Patent: 8,334,254
✉ Email this page to a colleague
Summary for Patent: 8,334,254
Title: | Recombinant lactoferrins, methods of production from plants and uses thereof |
Abstract: | The invention concerns the use of a recombinant nucleotide sequence containing a cDNA coding for a lactoferrin, in particular human lactoferrin, or the derived proteins, and elements enabling a plant cell to produce lactoferrin or the derived proteins, coded by the cDNA, in particular a transcription promoter and terminator identified by the plant cell transcription machinery, to transform plant cells in order to obtain, from these cells, or plants obtained therefrom, lactoferrin or derived proteins. |
Inventor(s): | Legrand; Dominique (Villeneuve d\'Ascq, FR), Salmon; Valerie (Montville, FR), Spik; Genevieve (Marcq en Barouel, FR), Gruber; Veronique (Chamalieres, FR), Bournat; Philippe (Clermont-Ferrand, FR), Merot; Bertrand (Volvic, FR) |
Assignee: | EDULIS (Lyon, FR) |
Application Number: | 12/099,462 |
Patent Claims: | see list of patent claims |
Details for Patent 8,334,254
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2017-05-02 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2017-05-02 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2017-05-02 | |
Baxalta Us Inc. | BIOCLATE (ARMOUR), RECOMBINATE | antihemophilic factor (recombinant) | For Injection | 103375 | 12/10/1992 | ⤷ Try a Trial | 2017-05-02 |
Baxalta Us Inc. | BIOCLATE (ARMOUR), RECOMBINATE | antihemophilic factor (recombinant) | For Injection | 103375 | 03/10/2010 | ⤷ Try a Trial | 2017-05-02 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |